Catalog No.
VHB87801
Species reactivity
Human
Host species
Human
Isotype
IgG1, lambda
Clonality
Monoclonal
Target
Plasma thromboplastin component, F9, Christmas factor, Coagulation factor IX, PTC
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00740
Applications
Blocking, ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
10C12
Multiplex, multimodal mapping of variant effects in secreted proteins., PMID:39975210
Intracranial hemorrhage in an infant leads to the diagnosis and treatment of severe hemophilia B: a case report., PMID:39609856
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives., PMID:39062568
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)., PMID:37962325
Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients., PMID:37722393
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications., PMID:35842956
The Clinical Genetics of Hemophilia B (Factor IX Deficiency)., PMID:34848993
Molecular analysis of severe hemophilia B in Indian families: Identification of mutational hotspot and novel variants., PMID:34590426
Haemophilia., PMID:34168126
Identification of zebrafish ortholog for human coagulation factor IX and its age-dependent expression., PMID:33974340
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)., PMID:33278853
Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations., PMID:32875744
The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges., PMID:32726826
Advances and challenges for hemophilia gene therapy., PMID:31332444
Gene Therapy for Hemophilia: Progress to Date., PMID:29127625
Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B., PMID:28007939
Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations., PMID:26612714
Risk factors associated with inhibitor development in Chinese patients with haemophilia B., PMID:25929987
Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B., PMID:25470321
Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4., PMID:25417755
[Haemophilia]., PMID:25351381
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B., PMID:24460861
Mutation analysis of a cohort of US patients with hemophilia B., PMID:24375831
Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B., PMID:23093250
Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B., PMID:22279442
F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity., PMID:22103590
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B., PMID:19603001
Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer., PMID:19309290
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy., PMID:15231566
Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors., PMID:11545612
Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9., PMID:11545610
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation., PMID:11545609
For research use only. Not for human or drug use.
